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INTRODUCTION
Pentraxins are a superfamily of soluble multi-functional pat-
tern recognition receptors.1 Pentraxin 3 (PTX3) is the prototyp-
ic long pentraxin, and the classic short pentraxin of C-reactive 
protein (CRP) and serum amyloid P component (SAP) are oth-
er key members of this family.1 PTX3 plays a major role in in-
nate immunity and inflammation.1 It is rapidly produced and 
released by various inflammatory cells in response to pro-in-
flammatory stimuli,2-4 and acts as an acute phase protein, simi-
lar to short pentraxins, because the plasma level of PTX3 in-
creases rapidly and drastically during inflammation.1 However, 
the normal human population without any inflammatory con-
ditions has a low plasma PTX3 level of <2 ng/mL.1 
Despite the introduction of updated early intensive resusci-
tating strategies and new antibiotics, sepsis-related morbidi-
ties and mortality remain considerably high.5-7 Therefore, new 
treatment strategies with immunomodulatory drugs such as 
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the targeted therapy according to the status of inflammatory re-
sponse in each patient need to be developed to dramatically 
improve outcomes, especially in septic patients with high se-
verity and risk of poor outcome. To achieve improvement, we 
must identify new prognostic biomarkers that can predict the 
mortality caused by severe sepsis, in spite of successful initial in-
tensive resuscitation.6-9 
Plasma PTX3 has been reported to be higher in patients with 
severe sepsis of high severity compared with healthy controls 
and patients with low severity sepsis.10-13 It has been suggested 
to be a good predictive marker of mortality in sepsis, because it 
may reflect tissue involvement by inflammatory processes 
more directly.1,14 However, there have been few studies to eval-
uate novel prognostic biomarkers including PTX3 to predict 
mortality in patients with severe sepsis receiving initial inten-
sive resuscitation. The aim of this study, therefore, was to eval-
uate the relationship between PTX3 and poor outcome, and 
also to explore the role of PTX3 as a predictive biomarker of 28-
day all-cause mortality in severe sepsis patients who received 
successful early goal-directed therapy (EGDT) and initial re-
suscitation according to Surviving Sepsis Campaign.6,15
MATERIALS AND METHODS
Study subjects and design 
A prospective cohort study was conducted at Severance Hos-
pital, a 2000-bed, tertiary-care, University-affiliated referral 
center located in Seoul, Republic of Korea. Total 474 patients 
visited at emergency department (ED) with presentation of the 
defined criteria for systemic inflammatory response syndrome 
(SIRS) by infection from July 2012 and April 2013. The 199 pa-
tients were eligible if they were ≥20 years of age and had the 
sustained sepsis-induced hypotension or ≥4 mmol/L of lactate 
in spite of adequate initial fluid resuscitation (20–30 mL/kg) 
with crystalloid6,15,16 as well as were receiving EGDT. We exclud-
ed 66 patients based on the following criteria: 1) pregnancy, 2) 
acute cerebrovascular accident, 3) acute coronary syndrome, 4) 
contraindication to central venous catheterization, 5) active gas-
trointestinal bleeding, 6) trauma, 7) drug overdose, 8) require-
ment of immediate surgery, and 9) do-not-resuscitate status. 
We prospectively enrolled 107 patients who had successfully 
undertaken EGDT, which was defined as the fulfillment of all 
EGDT components and achievement of the final goal of supe-
rior vena cava oxygen saturation (ScvO2) ≥70% within 6 hrs af-
ter arrival at the ED, as well as faithfully implemented EDGT 
and initial resuscitation of Surviving Sepsis Campaign interna-
tional guidelines for management of severe sepsis and septic 
shock according to the recent update version at enrollment.6,15,17 
We finally included total 83 participants in this prospective 
longitudinal study (Fig. 1). All participants were fulfilled with 
the definition for severe sepsis and septic shock.6,15,16
The primary outcome of this study was the 28-day all-cause 
mortality. Written informed consents were obtained from all 
patients before study enrollment. This study was approved by 
our local Ethic Committee of Institutional Review Board. 
Data collection 
The clinical characteristics and laboratory data of study par-
ticipants were collected from electronic medical records. The 
clinical characteristics included age, gender, body mass index 
(BMI), primary infectious origin, underlying comorbidities, 
Charlson index,18 Sepsis-related Organ Failure Assessment 
(SOFA) score19 assessed upon arrival at the ED, acute renal /
liver failure, bacteremia, methods for treatment of severe sep-
sis and appropriate initial empirical antibiotic use within 2 hrs 
from the arrival at the ED and the alive status on hospital day 
(HD) 0, 3, 7, 14, and 28. Acute Physiology and Chronic Health 
Evaluation II (APACHE II) score was assessed based on the 
worst values over the first 24 hrs of intensive care unit (ICU) 
care.20 Laboratory data included plasma procalcitonin (PCT; 
ng/mL), serum CRP (mg/L) and delta neutrophil index (DNI; 
Fig. 1. The flow chart on the enrollment processes for study participants. 
*This was defined as the fulfillment of all EGDT components and achieve-
ment of the final goal of superior vena cava oxygen saturation ≥70% 
within 6 hrs after arrival at the emergency department, as well as faithful-
ly implemented EGDT and initial resuscitation of Surviving Sepsis Cam-
paign international guidelines for management of severe sepsis and sep-
tic shock according to the recent update version at enrollment. EGDT, 
early goal-directed therapy.
Total patients who visited at emergency department
with presentation of sings for sepsis 
from July 2012 and April 2013 (n=474)
Patients who ≥20 years of age and  
were receiving EGDT (n=199)
[The sustained sepsis-induced hypotension or  
≥4 mmol/L of lactate in spite of adequate initial  
fluid resuscitation (20–30 mL/kg)]
The patients who had successfully undertaken  
EGDT* (n=107)
Final enrolled participants in the study (n=83)
Patients who did not have hypotension  
and organ dysfunction or who were  
<20 years of age (n=275)
Patients with any exclusion  
criteria (n=66)
Patients who did have successfully 
undertaken EGDT (n=26)
Patients who did not have given 
consent (n=24)
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%) measured at HD 0 (n=83), 3 (n=78), 7 (n=76), and 14 (n=70) 
from all alive patients at each HD. As the components of 
EGDT, the central venous pressure (CVP), mean arterial blood 
pressure (MAP) and ScvO2 values were measured and collected 
upon arrival at the ED (0 hr) and 2, 4, and 6 hrs upon arrival at 
the ED. 
Definitions 
HD 0 was defined as the time within 24 hrs after arrival at the 
ED. The other HDs were exactly calculated from HD 0 and 
consistently applied at all data collections and measurements 
of plasma PTX3. The survivors were defined as patients who 
were alive at HD 28 and the non-survivors were defined as pa-
tients who were dead by HD 28, irrespective of direct cause of 
death. The patients with any of the following criteria due to 
the infection were defined as severe sepsis; 1) sepsis-induced 
hypotension of systolic blood pressure (SBP) <90 mm Hg or MAP 
<70 mm Hg or SBP decrease >40 mm Hg, 2) lactate >4 mmol/L, 
3) urine output <0.5 mL/kg/hr for ≥2 hrs despite adequate flu-
id resuscitation, 4) acute lung injury, 5) creatinine (Cr) increase 
>0.5 mg/dL, 6) bilirubin >4 mg/dL, 7) platelet <100000/μL, 
and 8) international normalized ratio (INR) >1.5.6,15,16 Septic 
shock was defined as sepsis-induced hypotension persisting 
despite adequate fluid resuscitation.6,15,16 We used the defini-
tions of SIRS and sepsis by 2001 International Sepsis Defini-
tions Conference.16 Bacteremia was confined into the clinically 
significant bacteremia, which was defined as ≥1 positive blood 
culture performed before the first administration of antimi-
crobial agents and clinical features compatible with sepsis.21 
Acute renal failure was diagnosed as an absolute increase in 
serum Cr of 0.3 mg/dL over 48 hrs or a 50% increase in Cr over 
7 days according to Kidney Disease Improving Global Out-
comes.22 Acute liver failure referred to the development of se-
vere acute liver failure with encephalopathy and coagulopathy 
(INR ≥1.5) in a patient without prior known liver disease with-
in 26 wks of the onset of any hepatic symptoms.23 
DNI is evaluated by subtracting the fraction of mature poly-
morphonuclear leukocytes from the sum of myeloperoxidase-
reactive cells.24 Administration of low-dose steroid was defined 
as the use of intravenous hydrocortisone at a dose of 200 mg 
per day.25 The successful achievement of EGDT goals was de-
fined as attaining all of the following hemodynamic endpoints 
within 6 hrs upon arrival at the ED; 1) CVP≥8–12 mm Hg (12–15 
mm Hg in ventilated patients), 2) MAP≥65 mm Hg, 3) ScvO2≥ 
70%, and 4) urine output≥0.5 mL/kg/hr.26 
The measurement of plasma pentraxin 3 levels
Samples for PTX3 measurement were obtained from all living 
patients on HD 0, 3, 7, and 14. The plasma was stored at -70°C 
until analysis. PTX3 levels were measured by sandwiched ELI-
SA, using a commercial kit of Human PTX3/TSG-14 Quanti-
kine® Immunoassay (R&D Systems Inc., Minneapolis, MN, 
USA) with the detection limit of 0.1 ng/mL, according to the 
manufacturer’s instruction. We made the seven standard solu-
tions (from 20 ng/mL to 0.313 ng/mL) by serial 1:2 dilution with 
zero standard (0 ng/mL) for standard curve. The optical densi-
ties were measured at 450 nm using the Spectramax® 190 mi-
croplate reader (Molecular Devices, Sunnyvale, CA, USA). 
Each sample including standard solution was tested in tripli-
cate and the mean values were used in analyses. Both intra 
and interassay coefficients of variation were <10%. The PTX3 
does not cross-react with short pentraxin of CRP and SAP. 
 
Statistical analyses
Statistical analyses were performed using SPSS software, ver-
sion 20 (SPSS Inc., Chicago, IL, USA) and a two-sided p value 
less than 0.05 was considered as statistically significant. All 
data for continuous variables were presented as median (in-
terquartile range). Categorical variables were analyzed by χ2 
test or Fisher’s exact test, and continuous variables were ana-
lyzed by Mann-Whitney U test. The correlation between two 
continuous variables was evaluated by Pearson’s correlation 
coefficient (r). The differences in 28-day all-cause mortality by 
survival curve were compared using the log-rank test. The 
Cox’s proportional hazard model was computed to evaluate 
the independent predictive effect of initial PTX3 at HD 0 on 28-
day all-cause mortality and to find the independent predictive 
variables of 28-day all-cause mortality with the variables with 
p values less than 0.05 in univariate analyses. The accuracy 
and cut-off levels of initial PTX3, PCT, and DNI for predicting 
28-day all-cause mortality were investigated using receiver op-
erating characteristic (ROC) curves.27 Area under the ROC curve 
(AUC)ROC was expressed with 95% confidence interval (CI) and 
p value in each ROC curve.
RESULTS
The characteristics of study subjects
For the 83 enrolled subjects, the 28-day all-cause mortality was 
19.3%. The number of patients who died on HD 3, 7, 14, and 28 
was 5, 7, 13, and 16, respectively. The survivors (n=67) and 
non-survivors (n=16) were similar in age, gender, BMI and 
Charlson index including the frequency of various underlying 
comorbidities.
The APACHE II score was significantly higher in the non-sur-
vivors than in the survivors [20 (15–29) vs. 15 (12–19), p=0.011]. 
The frequency of acute liver failure in the non-survivors was 
significantly higher than that in the survivors (68.8% vs. 7.5%, 
p<0.001), but acute renal failure occurred at a similar frequen-
cy in the two groups. The most common primary infectious or-
igin of severe sepsis was the urinary tract and lung in the survivors 
(38.8%) and non-survivors (50%), respectively. The frequency of 
initial bacteremia concomitance was also not significantly dif-
ferent between the two groups (56.3% vs. 47.8%, p=0.588). 
Among the treatment modalities of severe sepsis according to 
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the Surviving Sepsis Campaign updated in 2008 and 2012,6,15 
mechanical ventilation and vasopressin use were significantly 
more frequent in the non-survivors than with the survivors 
(37.5% vs. 10.4%, p=0.016 and 31.3% vs. 4.5%, p=0.006). How-
ever, the frequencies of continuous renal replacement therapy, 
low-dose steroid treatment, norepinephrine use, and adminis-
Table 1. Comparison of Clinical Characteristics and Sepsis Treatment between Survivors and Non-Survivors 
Characteristics Total (n=83) Survivors (n=67) Non-survivors (n=16) p value
Age 71 (64–77) 71 (64–77) 70 (63–76) 0.599
Male (%) 47 (56.6) 37 (55.2) 10 (62.5) 0.598
BMI (kg/m2) 23 (20–26) 23 (20–25) 23 (21–26) 0.710
Charlson index 3 (2–4) 3 (2–4) 4 (3–5) 0.106
Underlying comorbidities 
Diabetes mellitus 28 (33.7) 23 (34.3) 5 (31.3) 0.815
Chronic kidney disease 12 (14.5) 8 (11.9) 4 (25.0) 0.233
Cardiovascular disease* 18 (21.7) 14 (20.9) 4 (25.0) 0.741
Cerebrovascular disease 19 (22.9) 17 (25.4) 2 (12.5) 0.340
Solid cancer 27 (32.5) 20 (29.9) 7 (43.8) 0.286
SOFA score 8 (6–9) 8 (6–9) 8 (6–10) 0.490
APACHE II score 16 (13–19) 15 (12–19) 20 (15–29) 0.011
Acute kidney failure 42 (50.6) 34 (50.7) 8 (50.0) 0.100
Acute liver failure 16 (19.3) 5 (7.5) 11 (68.8) <0.001
Primary infectious origin†
Urinary tract 30 (36.1) 26 (38.8) 4 (25.0) 0.392
Respiratory 29 (34.9) 21 (31.3) 8 (50.0) 0.242
Intra-abdomen 27 (32.5) 23 (34.3) 4 (25.0) 0.564
Bacteremia 41 (49.4) 32 (47.8) 9 (56.3) 0.588
Treatment of severe sepsis
CRRT 13 (15.7) 8 (11.9) 5 (31.3) 0.117
Mechanical ventilation 13 (15.7) 7 (10.4) 6 (37.5) 0.016
Low-dose steroid 42 (50.6) 31 (46.3) 11 (68.8) 0.164
Norepinephrine 69 (83.1) 56 (83.6) 13 (81.3) 1.000
Vasopressin 8 (9.6) 3 (4.5) 5 (31.3) 0.006
Appropriate empirical antibiotics use within 2 hr 73 (88.0) 58 (86.6) 15 (93.8) 0.678
Components of EGDT 
CVP (mm Hg) 
0 hr 6 (4–10) 6 (3–9) 6 (4–11) 0.491
2 hr 7 (5–10) 7 (5–9) 7 (4–11) 0.771
4 hr 8 (5–11) 9 (5–11) 8 (5–11) 0.364
6 hr 9 (6–12) 10 (6–12) 9 (5–11) 0.694
MAP (mm Hg)
0 hr 59 (50–69) 57 (50–68) 60 (56–71) 0.339
2 hr 71 (62–81) 71 (62–79) 68 (61–85) 0.798
4 hr 82 (75–91) 83 (75–92) 78 (67–85) 0.095
6 hr 85 (78–93) 87 (79–98) 77 (64–87) 0.009
SCVO2 (%)
0 hr 66 (58–72) 65 (59–71) 69 (54–76) 0.244
2 hr 68 (61–73) 67 (62–71) 71 (61–74) 0.371
4 hr 73 (61–78) 72 (60–77) 77 (64–86) 0.289
6 hr 79 (71–87) 77 (69–84) 83 (75–89) 0.105
Total hospital stay (days) 16 (8–24) 17 (11–29) 8 (3–13) <0.001
BMI, body mass index; SOFA, sequential organ failure assessment; APACHE, acute physiology and chronic health evaluation; CRRT, continuous renal replace-
ment therapy; EGDT, early goal-directed therapy; CVP, central venous pressure; MAP, mean arterial pressure; SCVO2, superior vena cava oxygenation saturation. 
Values are presented as the median (interquartile range) or number (percent). SOFA score was assessed upon arrival at the emergency department and APACHE 
II score was assessed based on the worst values over the first 24 hrs of intensive care unit care. 
*Except essential hypertension, †Multiple selection was possible in one patient.
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tration of the appropriate initial empirical antibiotics within 2 
hrs upon arrival at the ED were not different between the two 
groups. The detailed components of EGDT at 0, 2, 4, and 6 hrs 
were similar between the two groups, except for the MAP level 
at 6 hrs (Table 1).
Change of inflammatory markers at various 
hospital days
The levels of PTX3, PCT, CRP, and DNI continually decreased 
with time for all study subjects. In particular, only PTX3 pre-
sented with a consistent and significant difference for HD 0, 3, 
and 7 between the survivors and non-survivors. The non-sur-
vivors had a significantly higher PTX3 at HD 0, 3, 7, and 14 
than the levels in the survivors [HD 0: 201.4 (56.9–268.6) ng/mL 
vs. 36.5 (13.7–145.3) ng/mL, p=0.008; HD 3: 66.4 (49.3–146.1) 
ng/mL vs. 10.5 (8.5–17.3) ng/mL, p=0.002; HD 7: 49.7 (25.8–
163.6) ng/mL vs. 8.8 (7.7–11.8) ng/mL, p=0.003] (Fig. 2, Table 
2). Comparing with the 28-day all-cause mortality by quartile 
of PTX3 at HD 0, the mortality rates were higher in the groups 
with greater levels of PTX3 (Q1: 9.5%, Q2: 5.0%, Q3: 19.0%, Q4: 
38.1%, p=0.024). The PCT levels did not reveal any significant 
difference at all on HD 0, 3, and 7. The CRP levels showed sig-
nificantly higher values in the non-survivors at only HD 7. The 
DNI values showed significantly higher levels in the non-survi-
vors only at HD 0 (Table 2). 
The cut-off levels of various markers measured at HD 
0 for the prediction of 28-day all-cause mortality 
For PTX3, PCT, DNI, and CRP at HD 0, the largest and smallest 
AUCROC values for the prediction of 28-day all-cause mortality 
were for PTX3 and CRP, respectively (0.819, 95% CI 0.677–0.961, 
p=0.008 and 0.564, 95% CI 0.400–0.728, p=0.456, respectively). 
The most valid cut-off level to predict the 28-day mortality of 
PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7% and speci-
ficity 73.8%). In addition, the most appropriate cut-off points 
of DNI were 10.6% with the AUCROC values of 0.739 (95% CI 
0.591–0.887, p=0.003) (sensitivity 68.8% and specificity 77.6%) 
(Fig. 3A). The AUCROC values of APACHE II and SOFA score for 
the prediction of 28-day all-cause mortality (0.765 and 0.591, 
respectively) were smaller than PTX3 (Fig. 3B). 
Fig. 2. Changing pattern of PTX3 levels at HD 0, 3, and 7 in survivors and 
non-survivors. The middle and upper/lower error bars mean the median 
and interquartile ranges, respectively. PTX3, pentraxin 3; HD, hospital day.
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Table 2. Comparison of Inflammatory Markers Measured on Hospital day 0, 3, and 7 between Survivors and Non-Survivors
HD Total Survivors Non-survivors p value
PTX3 (ng/mL)
0 51.6 (14.3–197.6) 36.5 (13.7–145.3) 201.4 (56.9–268.6) 0.008
3 12.7 (8.7–34.1) 10.5 (8.5–17.3) 66.4 (49.3–146.1) 0.002
7 8.9 (7.8–13.5) 8.8 (7.7–11.8) 49.7 (25.8–163.6) 0.003
Procalcitonin (ng/mL)
0 9.9 (0.6–30.6) 7.8 (0.3–30.6) 17.4 (9.7–33.4) 0.114
3 8.2 (0.2–12.7) 5.2 (0.1–12.9) 4.5 (0.3–21.7) 0.909
7 0.6 (0.1–2.1) 0.6 (0.1–1.8) 1.6 (0.6–19.1) 0.113
CRP (mg/L)
0 106.1 (42.3–174.2) 106.1 (35.4–169.2) 117.0 (55.6–201.5) 0.723
3 64.1 (29.6–156.7) 64.1 (27.7–156.7) 58.8 (45.9–236.1) 0.634
7 36.3 (12.7–76.9) 35.3 (12.3–70.7) 102.5 (47.0–172.6) 0.004
DNI (%)
0 6.1 (1.9–13.6) 5.1 (1.3–10.0) 14.3 (5.8–50.1) 0.003
3 0.8 (0.0–2.9) 0.8 (0.0–2.1) 2.3 (0.4–4.1) 0.224
7 1.6 (0.1–3.0) 1.2 (0.0–3.0) 1.8 (1.7–4.7) 0.145
PTX3, pentraxin 3; CRP, C-reactive protein; DNI, delta neutrophil index; HD, hospital day.
Values are presented as the median (interquartile range). The number of total participants who received the measurement of above four inflammatory markers 
were 83, 78, and 76 at HD 0, 3, and 7, respectively. In survivors, the inflammatory markers were measured in 67 patients at all HD 0, 3, and 7. In non-survivors, 
the number of patient who received the measurement of the inflammatory markers were 16, 11, and 9 at HD 0, 3, and 7, respectively. 
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died by HD 28, but only 6 (10.7%) patients among the 56 pa-
tients with PTX3 level lower than 140 ng/mL at HD 0 were 
dead by HD 28. The percentage of subjects with PTX3 level 
greater than 140 ng/mL at HD 0 was significantly higher in the 
non-survivors than in the survivors [68.8% (11 of 16) vs. 23.9% 
(16 of 67), p=0.003].
Short-term change in plasma PTX3 level
We subtracted the PTX3 level at HD 3 from the PTX3 level at 
HD 0 to identify the effect of the short-term change in PTX3 
level on mortality. These short-term changes in values were 
significantly lower in the survivors than in the non-survivors 
[-33.0 (-154.0–-3.8) ng/mL vs. 84.9 (-5.4–259.3) ng/mL, p<0.001] 
(Fig. 4B). The plasma PTX3 levels at HD 3 showed decreasing 
values compared to those at HD 0 in 55 of 67 (82.1%) patients 
in the survivors. On the other hand, 8 of 11 (72.7%) patients in 
the non-survivors had a short-term increase in PTX3 level. The 
28-day cumulative survival rate was 80% (12 of 15) in patients 
with the short-term decrease in PTX3 level at HD 3 in spite of 
greater than 140 ng/mL level of PTX3 at HD 0. In addition, 11 
of 12 (91.7%) patients with PTX3 less than 140 ng/mL at HD 0 
were alive at HD 28 in spite of the short-term increase in PTX3 
value at HD 3.
DISCUSSION
Our present results suggest that the plasma PTX3 level mea-
sured within 24 hrs upon arrival at the ED could be a powerful 
Correlation of pentraxin 3 with various predictive 
markers according to hospital day
The PTX3 and PCT levels measured at HD 0 and 14 had a sig-
nificant correlation (r=0.675, p<0.001 and r=0.757, p<0.001). 
However, there was no significant correlation between the PTX3 
and PCT levels measured at HD 3 (r=-0.261, p=0.437). The sig-
nificant correlation between PTX3 and CRP levels was observed 
for HD 0, 3, 7, and 14 with an increase in correlation coefficient 
with time (HD 14: r=0.496, p=0.003). There was a significantly 
strong correlation between PTX3 and DNI only on HD 0 and 3 
(HD 0: r=0.507, p<0.001 and HD 3: r=0.911, p<0.001). The PTX3 
measured at HD 0 and SOFA/APACH II score assessed upon 
arrival at the ED/ICU had significant correlations with a low 
correlation coefficient (Table 3). 
 
Independent marker for the prediction of 28-day 
all-cause mortality 
In Cox’s proportional hazards model, the plasma PTX3 level 
measured at HD 0 was the only independent predictive marker 
for 28-day all-cause mortality in patients with severe sepsis 
who were receiving EGDT. The level of more than 140 ng/mL 
of PTX3 at HD 0 was correlated with a 7-fold increase in 28-day 
all-cause mortality [hazard rate (HR) 7.16, 95% CI 2.46–15.85, 
p=0.001] (Table 4). In addition, the 28-day cumulative survival 
rate in patients with a less than 140 ng/mL level of PTX3 at HD 
0 was significantly higher than in the patients with a level of 
PTX3 at HD 0 more than 140 ng/mL in Kaplan-Meier survival 
analysis (p=0.003) (Fig. 4A). Among the 27 patients with a PTX3 
level greater than 140 ng/mL at HD 0, 10 (37.0%) patients had 
Fig. 3. Comparison of ROC curves for inflammatory markers (A) and APACH II/SOFA score (B) measured at hospital day 0 for the prediction of 28-day all-
cause mortality. PTX3, delta neutrophil index, CRP and procalcitonin were measured at hospital day 0 within 24 hrs of arrival at the emergency depart-
ment. SOFA score was assessed upon arrival at the emergency department and APACHE II score was assessed based on the worst values over the first 
24 hrs of intensive care unit care. ROC, receiver operating characteristic; AUC, area under the ROC curve; CI, confidential interval; PTX3, pentraxin 3; PCT, 
procalcitonin; CRP, C-reactive protein; DNI, delta neutrophil index; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ fail-
ure assessment. 
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predictive biomarker for 28-day all-cause mortality in severe 
septic patients who have undertaken successful EGDT and ini-
tial resuscitation. The PTX3 level at HD 0 was the only inde-
pendent marker associated with 28-day all-cause mortality in 
Cox’s proportional hazards model. The patients with a PTX3 
level greater than 140 ng/mL at HD 0 had a 7-fold HR, and the 
mortality of these patients was as high as 68.8% in spite of the 
achievement at final goal of EGDT.
The plasma PTX3 level was previously evaluated to identify 
the association with the severity and mortality or the predic-
tion of development of bacteremia or septic shock, mainly in 
heterogeneous populations, including SIRS and/or severe sep-
sis and/or critically ill or febrile neutropenic hematologic pa-
tients.11-13,28,29 On the other hand, only a few studies on homo-
geneous infectious patients were performed to assess the role 
of PTX3 in severity or as a prognostic marker in patients with 
ventilator-associated pneumonia, community-acquired pneu-
monia, bacteremia, severe leptospirosis or severe meningo-
coccal disease.30-34 In spite of various infectious and/or inflam-
matory conditions, almost all the studies have shown that a 
higher level of PTX3 was related to severity or mortality, as in-
dicated by our data. However, our study is unique because of 
our approach in assessing the role of serial PTX3 for the pre-
diction of the mortality in the severe sepsis patients who have 
undertaken successful initial resuscitation. 
Physicians worldwide fight desperately against severe sepsis 
through implementation of the Surviving Sepsis Campaign 
guidelines to improve survival rate.6 The surviving sepsis cam-
paign guidelines are currently a very important strategy for 
treating severe sepsis because many clinical trials using new 
therapeutic drugs have not resulted in an improvement in 
mortality.6 The critical aspects of the Surviving Sepsis Cam-
paign are initial resuscitation, which prevents the occurrence 
of multi-organ failure within 6 hrs of arrival at the ED and is 
mainly performed through the process of EGDT.6 Therefore, 
the discovery of new prognostic markers and targeted therapy 
using new therapeutic drugs may be extremely important, es-
pecially in severe septic patients who are likely to die in spite of 
successful initial resuscitation. Considering such clinical im-
portance, we explored whether PTX3 is an independent pre-
dictive marker of 28-day mortality in the severe septic patients 
who have undertaken successful EGDT. 
The short-term change after HD 3 as well as initial PTX3 at 
HD 0 could be useful for predicting the 28-day mortality in 
specific conditions. These values were significantly higher in 
the non-survivors than in the survivors. Non-survivors had a 
high rate of short-term increase in PTX3, but almost all of the 
survivors had a decreasing pattern. The predictive role of initial 
PTX3 level at HD 0 for 28-day all-cause mortality was affected 
by short-term change after HD 3. The 28-day mortality was as 
low as 20% in patients with a decreased PTX3 after HD 3 in 
spite of PTX3 greater than 140 ng/mL at HD 0, which was the 
only independent predictive factor in Cox’s regression model. 
Therefore, if we assess both the PTX3 level at HD 0 and short-
term PTX3 change after HD 3, we could most likely obtain use-
ful information to predict 28-day all-cause mortality in severe 
septic patients who have undertaken successful EGDT.
Our data showed a strong correlation between PTX3 and 
PCT at HD 0 and 14, which is a well-known diagnostic and 
predictive biomarker for severity and mortality in sepsis.35 
However, initial PCT level at HD 0 was not an independent 
predictive marker for 28-day mortality, contrary to common 
expectations. The AUC value of PCT at HD 0 was lowest among 
Table 4. Independent Predictive Factors for 28-Day All-Cause Mortality 
in Severe Sepsis Patients Receiving Successful Early-Goal Directed 
Therapy 
Variables HR 95% CIs p value
Age≥71 yrs 3.27 0.57–10.69 0.377
Male 1.19 0.29–2.31 0.958
APACHE II score≥16 point 2.18 0.51–9.25 0.685
Mechanical ventilation 1.92 0.64–5.81 0.089
Acute liver injury 1.28 0.43–3.79 0.888
Vasopressin use 2.89 0.92–9.18 0.546
PTX3 at HD 0≥140 ng/mL 7.16 2.46–15.85 0.001
DNI at HD 0≥10.6% 1.23 0.13–9.03 0.217
HR, hazard rate; CI, confidence interval; APACHE, acute physiology and 
chronic health evaluation; PTX3, pentraxin 3; DNI, delta neutrophil index; HD, 
hospital day. 
Table 3. The Correlation of PTX3 with Other Inflammatory Markers 
Measured in All Participants Who were Alive at Each HD
HD r p value
PTX3 and procalcitonin
0 0.675 <0.001
3 -0.261 0.437
7 0.343 0.010
14 0.757 <0.001
PTX3 and CRP
0 0.253 0.024
3 0.268 0.044
7 0.308 0.022
14 0.496 0.003
PTX3 and DNI
0 0.507 <0.001
3 0.911 <0.001
7 0.085 0.533
14 0.268 0.132
PTX3 and APACHE II score at HD 0 0.242 0.042
PTX3 at HD 0 and SOFA score 0.390 0.001
PTX3, pentraxin 3; CRP, C-reactive protein; DNI, delta neutrophil index; 
APACHE, acute physiology and chronic health evaluation; SOFA, sequential 
organ failure assessment; HD, hospital day. 
r refers to the Pearson’s correlation coefficient. SOFA score was assessed 
upon arrival at the emergency department and APACHE II score was as-
sessed based on the worst values over the first 24 hrs of intensive care unit 
care. The number of patients at HD 0, 3, 7, and 14 were 83, 78, 76, and 70, 
respectively.
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PTX3 and DNI. Furthermore, we observed in the detailed pa-
tient description that there were obviously patients for whom 
PTX3 were helpful for predicting mortality, while PCT was not 
predictive: the patients who died due to severe sepsis from 
pneumonia had a high initial PTX3 level and increasing PTX3 
level at HD 7, irrespective of very low continuous PCT levels. 
In addition, the short-term change in PCT after HD 3 or 7 did 
not have predictive value for 28-day all-cause mortality. To 
our best knowledge, there have been no published study to 
assess the usefulness of PCT under EGDT or initial resuscita-
tion according to surviving sepsis campaign guidelines. Thus, 
further studies are warranted to identify any specific sepsis 
characteristics, such as the primary source of sepsis or specific 
clinical infectious circumstances, to establish the clinical utili-
ty of PTX3 as a biomarker for severe sepsis.
In the present study, we also evaluated the predictive role of 
DNI for 28-day mortality in severe septic patients who had 
undertaken successful EGDT and compared these values with 
PTX3. DNI, which are easily obtained as part of complete blood 
cell analysis and differential count can be determined without 
additional tests or additional cost, are new biomarkers for the 
prediction of severity and prognosis in sepsis.36-39 Nevertheless, 
there have been no published studies to evaluate these bio-
markers in severe septic patients who have undertaken suc-
cessful EGDT. 
In addition to important characteristics and homogeneity of 
our study population, our present study has several strengths 
and is unique in its approach to evaluate the prognostic role 
of PTX3 for mortality in severe sepsis. It has consistently been 
reported that initially high plasma PTX3 levels are associated 
with mortality or fatality in patients with inflammation by in-
fection, including severe sepsis.12,13,29,31 In the present study, we 
found much higher overall mean or median PTX3 at HD 0 than 
in previously reported studies (122.0 ng/mL in our study, 7.8 
ng/mL in bacteremia patients by Huttunen, et al.,31 and 16.7 
ng/mL in 49 severe sepsis patients by Uusitalo-Seppälä, et al.,12 
71.3 ng/mL in patients admitted to an ICU with SIRS by Bas-
trup-Birk, et al.13). Our high overall initial PTX3 level was simi-
lar to 118 ng/mL in the subgroup analysis carried out by Bas-
trup-Birk, et al.13 These findings, along with 19.3% of total 28-
day all-cause mortality and 16.2 of total APACHE II score in 
our study, suggest that the severity of sepsis in our study pop-
ulation was as high as those in severe septic patients encoun-
tered during routine clinical practice, although a direct com-
parison was impossible because of the absence of an APACHE 
II score in other studies.
The cut-off point for the prediction of mortality was higher 
in our study than in previously reported studies (140 ng/mL in 
our study, 15 ng/mL by Huttunen, et al.,31 7.7 ng/mL by Uusitalo-
Seppälä, et al.,12 and 32.6 ng/mL by Bastrup-Birk, et al.13) The 
AUCROC of PTX3 for the prediction of mortality in our study was 
as high as those in previously reported studies (0.819 in our 
study, 0.82 by Huttunen, et al,31 and 0.69 by Uusitalo-Seppälä, 
et al.12). Mauri, et al.29 reported that the high PTX3 HD 5: HD 0 
ratio may be associated with mortality in the 90 severe septic 
patients who were most similar to our study population among 
the studies for PTX3 and infection. In contrast to our study, how-
ever, the initial PTX3 levels in the study of Mauri, et al.29 were not 
different between non-survivors and survivors. 
The main weakness of our study is relatively small number 
of enrolled study participants. We prospectively enrolled pa-
tients with an accurate definition of severe sepsis and success-
ful achievement of EGDT, which is the core strategy of initial 
intensive resuscitation in the surviving sepsis campaign guide-
lines, and we obtained the results to suggest the powerful pre-
dictive role of initial PTX3. Therefore, our results have significant 
clinical relevance, and further studies for PTX3 are warranted, 
especially in septic patients with high severity and mortality irre-
spective of initial intensive resuscitation. Most recently, Cunha, 
et al.40 analyzed the association between the single-nucleotide 
polymorphisms in the PTX3 gene and the risk of invasive as-
pergillosis, and suggested an important role of PTX3 in critical 
Fig. 4. Kaplan-Meier survival curve according to PTX3 level on hospital day 0 with a cut-off point of 140 ng/mL (A) and comparison of short-term change in 
PTX3 level between hospital day 0 and 3 in both survivors and non-survivors (B). PTX3, pentraxin 3; HD, hospital day.
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infectious diseases. 
In conclusion, we found that the initial plasma PTX3 at HD 0 
is a strong predictive biomarker for 28-day all-cause mortality 
of severe sepsis patients who have undergone successful EGDT. 
The PCT level at HD 0 has a strong correlation with PTX3, how-
ever, it can not independently predict mortality. These findings 
suggest that PTX3 could play an important prognostic role in 
severe septic patients who received successful implantation of 
initial resuscitation. 
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